Pharmaceutical

Claiming R&D in Pharma, Medicine, and the Wider Medical Industry – Our Guide

Updated :
July 20, 2023
Published :
July 18, 2021
Back to sector guides
Table of content
Summary of article

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Share this to inspire, and educate
support image

£4.8 billion spent on R&D in 2019

financial image

Pharmaceuticals is one of the highest claiming sectors

agriculture image

29,000 people directly employed in R&D roles

Finding new or more efficient production methods of medicines or machinery is a key role of the pharmaceutical industry and contains lots of opportunities for R&D. Adapting the manufacture of medical machinery to improve overall efficiency will also continue to grow the sector.

Introduction to R&D Tax Credits in Pharma & Medicine

The pharmaceutical industry relies on developing medicines and products that benefit public health and the healthcare industry. The importance and the scale of this industry has been brought to the forefront of everyone’s mind, as we have all witnessed the work of UK scientists, technologists and researchers to overcome challenges faced by the COVID-19 crisis. The remarkable development of new vaccinations during this time is a clear example of R&D, but improvements in the efficiency of ventilators or production of hand sanitiser could also easily qualify as R&D. As the population continues to require new and improved methods of healthcare, the pharmaceuticals industry will continue to improve, with some specific examples outlined below.

Trends in Pharmaceuticals

Enhanced efficiency and implementation of new features

Finding new or more efficient production methods of medicines or machinery is a key role of the pharmaceutical industry and contains lots of opportunities for R&D. Adapting the manufacture of medical machinery to improve overall efficiency will also continue to grow the sector. It is also often required to implement new features into an existing product or develop a system with new properties to suit a client’s needs.

Investigation into new materials

It is often beneficial to investigate different materials that could be used in the production of medical machinery. To find improvements in design, perhaps by reducing construction/material costs, whilst ensuring the functionality requires R&D and will continue to be a trend in pharmaceuticals. This is likely to continue as people search for ways to improve the environmental impact of production whilst keeping up with the high standards demanded by the industry.

Example of R&D in the pharmaceutical industry

Development of anti-bacterial gels from alternative sources

The pharmaceutical industry undertakes intense R&D in the UK, with over £4 billion spent on R&D each year. The constant development of new and improved compounds and products sits very well within the government definition of R&D. The development of hand gels from alternative sources has been an example of some of the work undertaken recently. These hand gels had to be as effective as conventional hand gels but manufactured using materials from a distillery.

Conventional hand gels are produced using industrial-grade alcohols, with purity up to 99%. In order to achieve a hand gel with an equivalent efficacy using distillery-sourced alcohol, testing and reformulations had to be undertaken. Additives including thickeners and fragrances had to be altered to produce a product that was well received by consumers whilst also remaining cost effective.

What doesn’t qualify as R&D

Whilst market research can lead to R&D being undertaken based on the feedback, market research in itself is not R&D and would not be claimable. Work to make a product more cost-effective that was resolved easily would also be unlikely to qualify as R&D.

How can we help?

Jack Duddridge has relevant experience in the pharmaceutical sector and is able to use his background in chemistry to understand the challenges faced in-depth and tailor this to the BEIS guidelines. Book your free consultation to discover qualifying activities in your business and see how much your claim could be worth.

Jack Duddridge
R&D Tax Consultant

Related articles

Posted :
21 Nov 2024
New
Navigating the complexities of Patent Box claims: expert tips and pitfalls to avoid
Catalina Lohmeier
Chief of Staff
21 Nov 2024
Navigating the complexities of Patent Box claims: expert tips and pitfalls to avoid
January 16, 2025
Navigating the complexities of Patent Box claims: expert tips and pitfalls to avoid
Catalina Lohmeier
Chief of Staff
Posted :
21 Nov 2024
New
HMRC tribunal ruling: landmark decision on client-led R&D tax relief
Olly Newman
R&D Technical Manager
21 Nov 2024
HMRC tribunal ruling: landmark decision on client-led R&D tax relief
January 16, 2025
HMRC tribunal ruling: landmark decision on client-led R&D tax relief
Olly Newman
R&D Technical Manager
Navigating the complexities of Patent Box claims: expert tips and pitfalls to avoid
January 16, 2025
HMRC tribunal ruling: landmark decision on client-led R&D tax relief
January 16, 2025
Unlocking growth potential with Smart Grants: a comprehensive guide for SMEs
January 16, 2025
Maximising R&D tax relief: how Patent Box can elevate your innovation strategy
January 16, 2025
Navigating the post-award management of Innovate UK grants: essential guidance for SMEs
January 16, 2025
How to Navigate HMRC Enquires into R&D Tax Credit Claims
January 16, 2025
How to Know Your R&D Spend is Appropriate?
January 16, 2025
Autumn Budget 2024: R&D relief protected in Labour’s first Budget
January 16, 2025
Updates From HMRC's R&D Communication Forum
January 16, 2025